EDITFORCE AND SOLASIA ENTER INTO JOINT R&D AGREEMENT
Tokyo and Fukuoka, December 26, 2019 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, President and CEO: Yoshihiro Arai, hereafter “Solasia”) and EditForce Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono, hereafter “EditForce”) announced today that the companies have entered into a joint R&D agreement to research and develop pharmaceutical drugs primarily in the field of oncology based on EditForce’s DNA/RNA editing technology.
Solasia and EditForce will design multiple projects (varying by the target disease, target gene sequence, and mechanism of action) based on RNA editing mainly in the oncology field, and through these projects, develop drugs utilizing the pentatricopeptide repeat (PPR) protein platform technology.
Please see the PDF link for more information.
(PDF)EDITFORCE AND SOLASIA ENTER INTO JOINT R&D AGREEMENT